Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy

Following FDA approval of trastuzumab in 1998 and lapatinib in 2007, several clinical studies have addressed the question of whether trastuzumab and lapatinib combination therapy is better than trastuzumab alone in the metastatic breast cancer and neoadjuvant setting. In this review, updated to Sept...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Eugene R., Wang, Emilie, Glück, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512454/
https://www.ncbi.nlm.nih.gov/pubmed/23226023
http://dx.doi.org/10.4137/BCBCR.S9301

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3512454/
https://www.ncbi.nlm.nih.gov/pubmed/23226023
http://dx.doi.org/10.4137/BCBCR.S9301

Ejemplares similares